Role of T cell immune response cDNA 7 on the pathology of acute graft‑versus‑host disease

Zhu,Feng; Xu,Yanqiu; Fan,Xiaohui; Zhang,Fan; Wang,Dong; Qiao,Jianlin; Zhu,Shengyun; Zhao,Kai; Pan,Bin; Chen,Chong; Zeng,Lingyu; Li,Zhenyu; Xu,Kailin

doi:10.3892/ol.2020.12163

Role of T cell immune response cDNA 7 on the pathology of acute graft‑versus‑host disease

Authors:
- Feng Zhu
- Yanqiu Xu
- Xiaohui Fan
- Fan Zhang
- Dong Wang
- Jianlin Qiao
- Shengyun Zhu
- Kai Zhao
- Bin Pan
- Chong Chen
- Lingyu Zeng
- Zhenyu Li
- Kailin Xu
View Affiliations

Affiliations: Blood Disease Institute, Xuzhou Medical University, Xuzhou, Jiangsu 221002, P.R. China
Published online on: September 28, 2020 https://doi.org/10.3892/ol.2020.12163
Article Number: 300
Copyright: © Zhu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Activation of T lymphocytes is the initiating factor of the occurrence of acute graft‑versus‑host disease (aGVHD), and cytotoxic T lymphocyte antigen‑4 (CTLA‑4) is the inhibitory receptor for activating T cells. T cell immune response cDNA 7 (TIRC7) is considered an upstream regulator of CTLA‑4; however, little is understood regarding the effects of TIRC7 on the regulation of CTLA‑4 in aGVHD. The purpose of the present study was to evaluate the regulatory effects of TIRC7 on aGVHD, mainly in the pathology. Recipient mice were exposed to a preconditioning dose of 7.5 Gy irradiation on the day of the transplantation and were divided into the following groups: Blank control group, bone marrow transplantation control group, total body irradiation group, mild‑moderate aGVHD group and severe aGVHD group. According to the different administration of CTLA‑4 and TIRC7 monoclonal antibodies, the mild‑moderate and severe aGVHD groups were randomly divided into the hematopoietic stem cell transplantation (HSCT) and HSCT + CTLA‑4/TIRC7 groups. Recipient mice were sacrificed at different time points post‑HSCT for histopathological analysis by hematoxylin and eosin staining. Compared with the control and other experimental groups, the mice in the combined CTLA‑4 and TIRC7 group exhibited ameliorated pathological injury, and lower pathology scores of the liver, lung and intestine. These data revealed that intraperitoneal injection of anti‑TIRC7 and/or anti‑CTLA‑4 monoclonal antibody into mice could effectively alleviate the severity of aGVHD.

View Figures

View References

1	Ammer J, Prantl L, Holler B, Holler K, Landfried D, Wolff S, Karrer R, Andreesen R and Holler E: Successful treatment of a refractory skin ulcer in chronic cutaneous GvHD after allogeneic HSCT with split-thickness skin allografting from the stem cell donor. Bone Marrow Transplant. 47:1368–1369. 2002. View Article : Google Scholar
2	Ferrara JL, Levine JE, Reddy P and Holler E: Graft-versus-host disease. Lancet. 373:1550–1561. 2009. View Article : Google Scholar : PubMed/NCBI
3	Lai HY, Chou TY, Tzeng CH and Lee OK: Cytokine profiles in various graft-versus-host disease target organs following hematopoietic stem cell transplantation. Cell Transplant. 21:2033–2045. 2012. View Article : Google Scholar : PubMed/NCBI
4	Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA and Sharpe AH: Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity. 3:541–547. 1995. View Article : Google Scholar : PubMed/NCBI
5	Fevery S, Billiau AD, Sprangers B, Rutgeerts O, Lenaerts C, Goebels J, Landuyt W, Kasran A, Boon L, Sagaert X, et al: CTLA-4 blockade in murine bone marrow chimeras induces a host-derived antileukemic effect without graft-versus-host disease. Leukemia. 21:1451–1459. 2007. View Article : Google Scholar : PubMed/NCBI
6	Zhu F, Zhong XM, Qiao J, Liu Q, Sun HY, Chen W, Zhao K, Wu QY, Cao J, Sang W, et al: Cytotoxic T Lymphocyte Antigen-4 Down-Regulates T Helper 1 cells by increasing expression of signal transducer and activator of transcription 3 in Acute Graft-versus-Host Disease. Biol Blood Marrow Transplant. 22:212–219. 2016. View Article : Google Scholar : PubMed/NCBI
7	Kumamoto Y, Tomschegg A, Bennai-Sanfourche F, Boerner A, Kaser A, Schmidt-Knosalla I, Heinemann T, Schlawinsky M, Blumberg RS, Volk HD and Utku N: Monoclonal antibody specific for TIRC7 induces donor-specific anergy and prevents rejection of cardiac allografts in mice. Am J Transplant. 4:505–514. 2004. View Article : Google Scholar : PubMed/NCBI
8	Morgun A, Shulzhenko N, Diniz RV, Almeida DR, Carvalho AC and Gerbase-DeLima M: Cytokine and TIRC7 mRNA expression during acute rejection in cardiac allograft recipients. Transplant Proc. 33:1610–1611. 2001. View Article : Google Scholar : PubMed/NCBI
9	Kumamoto Y, Tamura A, Volk HD, Reinke P, Lohler J, Tullius SG and Utku N: TIRC7 is induced in rejected human kidneys and anti-TIRC7 mAb with FK506 prolongs survival of kidney allografts in rats. Transpl Immunol. 16:238–244. 2006. View Article : Google Scholar : PubMed/NCBI
10	Utku N, Heinemann T, Tullius SG, Bulwin GC, Beinke S, Blumberg RS, Beato F, Randall J, Kojima R, Busconi L, et al: Prevention of acute allograft rejection by antibody targeting of TIRC7, a novel T cell membrane protein. Immunity. 9:509–518. 1998. View Article : Google Scholar : PubMed/NCBI
11	Utku N, Heinemann T, Winter M, Bulwin GC, Schlawinsky M, Fraser P, Nieuwenhuis EE, Volk HD and Blumberg RS: Antibody targeting of TIRC7 results in significant therapeutic effects on collagen-induced arthritis in mice. Clin Exp Immunol. 144:142–151. 2006. View Article : Google Scholar : PubMed/NCBI
12	Shulzhenko N, Morgun A, Rampim GF, Franco M, Almeida DR, Diniz RV, Carvalho AC and Gerbase-DeLima M: Monitoring of intragraft and peripheral blood TIRC7 expression as a diagnostic tool for acute cardiac rejection in humans. Hum Immunol. 62:342–347. 2001. View Article : Google Scholar : PubMed/NCBI
13	Zhu F, Qiao JL, Wu QY, Cao J, Zeng LY, Li ZY and Xu KL: Elevated levels of T-cell immune response cDNA 7 in patients with immune thrombocytopenia. Hematology. 19:477–482. 2014. View Article : Google Scholar : PubMed/NCBI
14	Utku N, Heinemann T and Milford EL: T-cell immune response cDNA 7 in allograft rejection and inflammation. Curr Opin Investig Drugs. 8:401–410. 2007.PubMed/NCBI
15	Heinemann T, Bulwin GC, Randall J, Schnieders B, Schnieders K, Volk HD, Milford E, Gullans SR and Utku N: Genomic organization of the gene coding for TIRC7, a novel membrane protein essential for T cell activation. Genomics. 57:398–406. 1999. View Article : Google Scholar : PubMed/NCBI
16	Bulwin GC, Heinemann T, Bugge V, Winter M, Lohan A, Schlawinsky M, Schulze A, Walter S, Sabat R, Schulein R, et al: TIRC7 inhibits T cell proliferation by modulation of CTLA-4 expression. J Immunol. 177:6833–6841. 2006. View Article : Google Scholar : PubMed/NCBI
17	Frischer JM, Reindl M, Kunz B, Berger T, Schmidt S, Milford EL, Knosp E, Lassmann H and Utku N: TIRC7 and HLA-DR axis contributes to inflammation in multiple sclerosis. Mult Scler. 20:1171–1181. 2014. View Article : Google Scholar : PubMed/NCBI
18	Zhu F, Qiao J, Chen W, Pan B, Wu QY, Cao J, Sang W, Yan ZL, Zeng LY, Li ZY and Xu KL: Increased expression of T cell immune response cDNA 7 in patients with acute graft-versus-host disease. Ann Hematol. 94:1025–1032. 2015. View Article : Google Scholar : PubMed/NCBI
19	Utku N, Boerner A, Tomschegg A, Bennai-Sanfourche F, Bulwi GC, Heinemann T, Loehler J, Blumberg RS and Volk HD: TIRC7 deficiency causes in vitro and in vivo augmentation of T and B cell activation and cytokine response. J Immunol. 173:2342–2352. 2004. View Article : Google Scholar : PubMed/NCBI
20	Li J, Semple K, Suh WK, Liu C, Chen F, Blazar BR and Yu XZ: Roles of CD28, CTLA4, and inducible costimulator in acute graft-versus-host disease in mice. Biol Blood Marrow Transplant. 17:962–969. 2011. View Article : Google Scholar : PubMed/NCBI
21	Chen W, Li M, Li Z, Yan Z, Cheng H, Pan B, Cao J, Chen C, Zeng L and Xu K: CXCR4-transduced mesenchymal stem cells protect mice against graft-versus-host disease. Immunol Lett. 143:161–169. 2012. View Article : Google Scholar : PubMed/NCBI
22	Zhao K, Zhao D, Huang D, Song X, Chen C, Pan B, Wu Q, Cao J, Yao Y, Zeng L and Xu K: The identification and characteristics of IL-22-producing T cells in acute graft-versus-host disease following allogeneic bone marrow transplantation. Immunobiology. 218:1505–1513. 2013. View Article : Google Scholar : PubMed/NCBI
23	Zhu S, Shi P, Lv C, Li H, Pan B, Chen W, Zhao K, Yan Z, Chen C, Loake GJ, et al: Loss of NLRP3 function alleviates murine hepatic graft-versus-host disease. Biol Blood Marrow Transplant. 24:2409–2417. 2018. View Article : Google Scholar : PubMed/NCBI
24	Blazar BR, Taylor PA, McElmurry R, Tian L, Panoskaltsis-Mortari A, Lam S, Lees C, Waldschmidt T and Vallera DA: Engraftment of severe combined immune deficient mice receiving allogeneic bone marrow via In utero or postnatal transfer. Blood. 92:3949–3959. 1998. View Article : Google Scholar : PubMed/NCBI
25	Kaplan DH, Anderson BE, McNiff JM, Jain D, Shlomchik MJ and Shlomchik WD: Target antigens determine graft-versus-host disease phenotype. J Immunol. 173:5467–5475. 2004. View Article : Google Scholar : PubMed/NCBI
26	Qian L, Wu Z and Shen J: Advances in the treatment of acute graft-versus-host disease. J Cell Mol Med. 17:966–975. 2013. View Article : Google Scholar : PubMed/NCBI
27	Alegre ML, Frauwirth KA and Thompson CB: T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol. 1:220–228. 2001. View Article : Google Scholar : PubMed/NCBI
28	Zheng J, Liu Y, Liu Y, Liu M, Xiang Z, Lam KT, Lewis DB, Lau YL and Tu W: Human CD8⁺ regulatory T cells inhibit GVHD and preserve general immunity in humanized mice. Sci Transl Med. 5:168ra92013. View Article : Google Scholar : PubMed/NCBI
29	Yoo JS, Lee YJ, Yoon JW, Hyunget KE and Hwang KW: CTLA-4-Tg/CD-28-KO mice exhibit reduced t cell proliferation in vivo compared to CD-28-KO mice in a graft-versus-host disease model. Korean J Physiol Pharmacol. 16:349–353. 2012. View Article : Google Scholar : PubMed/NCBI
30	Zhu F, Qiao J, Zhong XM, Wu QY, Chen W, Yao Y, Niu MS, Fu CL, Zeng LY, Li ZY and Xu KL: Antithymocyte globulin combined with cyclosporine A down-regulates T helper 1 cells by modulating T cell immune response cDNA 7 in aplastic anemia. Med Oncol. 32:1972015. View Article : Google Scholar : PubMed/NCBI
31	Tamura A, Milford EL and Utku N: TIRC7 pathway as a target for preventing allograft rejection. Drug News Perspect. 18:103–108. 2005. View Article : Google Scholar : PubMed/NCBI
32	Hwang KW, Sweatt WB, Brown IE, Blank C, Gajewski TF, Bluestone JA and Alegre ML: Cutting edge: Targeted ligation of CTLA-4 in vivo by membrane-bound anti-CTLA-4 antibody prevents rejection of allogeneic cells. J Immunol. 169:633–637. 2002. View Article : Google Scholar : PubMed/NCBI
33	Krummel MF, Sullivan TJ and Allison JP: Superantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivo. Int Immunol. 8:519–523. 1996. View Article : Google Scholar : PubMed/NCBI